{"id":"icm-adx-2191-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Ocular discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ADX-2191 works by targeting reactive aldehydes and aldehyde-producing pathways that drive pathological immune activation and inflammation. By modulating aldehyde metabolism and reducing aldehyde-mediated immune dysregulation, the drug aims to restore immune homeostasis and reduce inflammatory disease activity. This mechanism is designed to address conditions driven by aberrant aldehyde-mediated immune activation.","oneSentence":"ADX-2191 is a reactive aldehyde species that inhibits aldehyde dehydrogenase (ALDH) to modulate immune and inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:27.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"},{"name":"Ocular surface disease"}]},"trialDetails":[{"nctId":"NCT07402876","phase":"PHASE3","title":"A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma","status":"RECRUITING","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2026-02","conditions":"Primary Vitreoretinal Lymphoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":377,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ICM ADX-2191 injection","genericName":"ICM ADX-2191 injection","companyName":"Aldeyra Therapeutics, Inc.","companyId":"aldeyra-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ICM ADX-2191 injection is being studied in a clinical trial for the treatment of Primary Vitreoretinal Lymphoma. The mechanism of action of ICM ADX-2191 injection is currently unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}